Dechra receives FDA approval for first US generic entrant antibiotic

Is the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business

The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business and demonstrates the capabilities of their specialist pharma team, a key resource to the Group.

Commenting on the approval, Dechra's CEO, Ian Page said: "We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business while further enhancing Dechra's position in the US market."